- <![CDATA[EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression]]><![CDATA[In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosi…onclive · 2mo ago↗ source
- <![CDATA[New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons]]><![CDATA[Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.]]>onclive · 2mo ago↗ source
- Cytospire hauls in $83M for a new type of T cell engager<p>The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies. </p>